Cited by 61Neurotransmitter Receptor Influence on BehaviorTreatment of Major DepressionPharmacogenetics and Drug Metabolism

Pharmacogenomic evaluation of the antidepressant citalopram in the mouse tail suspension test

Open access
Crowley, James J, Brodkin, Edward S, Blendy, Julie A, Berrettini, Wade H, Lucki, Irwin·2006·Neuropsychopharmacology

Abstract

The identification of genetic variants regulating antidepressant response in human patients would allow for more individualized, rational, and successful drug treatments. We have previously identified the BALB/cJ inbred mouse strain as highly responsive to the selective serotonin reuptake inhibitor (SSRI) citalopram in the tail suspension test (TST), a widely used and well-established screening paradigm for detecting compounds with antidepressant activity. In contrast, A/J mice did not show a significant response to citalopram in this test despite exposure to equivalent plasma levels of the drug. To identify genetic determinants of this differential response, 506 F2 mice from an intercross between BALB/cJ and A/J mice were phenotyped. Composite interval mapping of 92 mice from the phenotypic extremes revealed three loci on chromosomes 7, 12, and 19 affecting citalopram response in the TST. The quantitative trait locus (QTL) at the telomeric end of chromosome 19 showed the greatest level of significance. Three candidate genes residing in this locus include those for vesicular monoamine transporter 2 (VMAT2, slc18a2), alpha 2A adrenergic receptor (adra2a), and beta 1 adrenergic receptor (adrb1). The protein coding regions of these three genes in BALB/cJ and A/J mice were sequenced and two polymorphisms were found in VMAT2 (Leu117Pro and Ser505Pro), while the transcribed regions of adra2a and adrb1 were of identical sequence between strains. Follow-up studies are needed to determine if the VMAT2 polymorphisms are functional and if they could explain the chromosome 19 QTL. The present quantitative trait study suggests possible candidate genes for human pharmacogenetic studies of therapeutic responses to SSRIs such as citalopram.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/sj.npp.1301065

Cites

59 of 59 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Crowley, J. J., Brodkin, E. S., Blendy, J. A., Berrettini, W. H., & Lucki, I.
Affiliations
University of Pennsylvania (US)
Corresponding author
Lucki, Irwin
Venue
Neuropsychopharmacology
Published
2006-03-22
Volume
31
Issue
11
Pages
2433-2442
ISSN
  • 0893-133X (ISSN-L)
  • 1740-634X
OpenAlex
W2016095427
Cited by
61
References
59
Citations by year
2025: 1 · 2024: 1 · 2022: 1 · 2021: 4 · 2020: 1 · 2019: 4 · 2016: 3 · 2015: 1 · 2014: 5 · 2013: 6 · 2012: 2
FWCI
2.66
Type
journal article
Language
en
Open access
Licence
Locations
  • Neuropsychopharmacology (publishedVersion, public-domain)
  • PubMed (publishedVersion)
Funders
  • Burroughs Wellcome Fund
  • U.S. Public Health Service
  • National Institute of Mental Health (K08MH068586, MH14652, MH 48152)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
  • Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
Keywords
citalopram, pharmacogenomics, antidepressant response, tail suspension test, selective serotonin reuptake inhibitors, BALB/cJ mice, A/J mice, F2 intercross, quantitative trait loci, chromosome 19, vesicular monoamine transporter 2, ADRA2A, ADRB1, candidate genes, genetic determinants of drug response
MeSH terms
Animals, Behavior, Animal, Cattle, Pan troglodytes, Chromosome Mapping, Female, Genetic Testing, Humans, Male, Mice, Inbred A, Mice, Inbred BALB C, Pharmacogenetics, Citalopram, Antidepressive Agents, Second-Generation, Hindlimb Suspension, Quantitative Trait Loci, Immobility Response, Tonic, Mice, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review